The innovative pharmaceutical market continues to expand, with capital increasingly favoring the Hong Kong Stock Connect healthcare sector.
Release date:
2023-03-02
According to a report by the Qianzhan Industry Research Institute, China's innovative pharmaceutical market has experienced rapid growth, driven by favorable policies, dynamic adjustments in medical insurance, and increased R&D investments.
According to a report by the Foresight Industry Research Institute, China's innovative pharmaceutical market has experienced rapid growth, driven by favorable policies, dynamic adjustments in medical insurance, and increased R&D investments. Preliminary statistics from Frost & Sullivan reveal that the country's innovative pharmaceutical industry reached a market size exceeding 1.13 trillion yuan in 2024. As the market continues to expand, the investment value of related indices has become increasingly prominent. The CSI Hong Kong Stock Connect Pharmaceutical & Healthcare Composite Index comprises 50 highly liquid, large-cap healthcare stocks listed within the Hong Kong Stock Connect program. Recently, the Hong Kong Stock Connect Pharmaceutical ETF (513200) has seen net inflows for two consecutive weeks, totaling over 500 million yuan. Its low management fee—just 0.15% annually—has attracted numerous investors, making it an excellent choice for gaining exposure to leading companies in the pharmaceutical sector. This trend reflects the market's sustained optimism toward the pharmaceutical industry, particularly the innovative drug segment.
Related News
Company Address: Zone C, Specialized & Innovative Chemical Industry Incubation Base, West Section of Yili River Street, No. 436, Qinchuan Town, Qinchuan Park, Lanzhou New Area, Gansu Province
Mobile Phone Official Website